Skip to content

Prenylflavanoids as a biomarker of beer consumption

Urinary isoxanthohumol excretion as a biomarker of beer consumption

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN72996101
Enrollment
41
Registered
2013-05-16
Start date
2011-03-31
Completion date
Unknown
Last updated
2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Beer consumption Nutritional, Metabolic, Endocrine

Interventions

Male volunteers: Intervention 1: Administration of 330 mL beer (14.5 g ethanol) Intervention 2: Administration of 660 mL beer (29 g ethanol) Intervention 3: Administration of 990 mL beer (43.5 g et

Sponsors

Center for Biomedical Research in Pathophysiology of Obesity & Nutrition (Ciber Fisiopatología de la Obesidad Nutrición)(Spain)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Young healthy volunteers of age 28±3 years, body mass index 22.69±2.69 kg/m2

Exclusion criteria

Exclusion criteria: 1. Previous history of cardiovascular disease (ischemic heart disease criteria - angina, recent or old myocardial infarction, cerebral vascular accident or peripheral vascular disease) 2. Homeostatic disorders 3. Any several chronic diseases 4. Hypertension or dyslipidemia 5. Smoking subjects 6. Alcoholism 7. Other toxic abuse

Design outcomes

Primary

MeasureTime frame
Concentrations of urinary prenylflavanoids will be determined by liquid chromatography coupled to tandem mass spectrometry (LC?MS/MS). These determinations will be carried out in first morning urine samples collected the day before the first intervention and in the subsequent mornings following each intervention. Creatinine adjustment will be used to normalize analyte concentrations in these urine samples.

Secondary

MeasureTime frame
No secondary outcome measures

Countries

Spain

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026